CLS Americas Debuts MRI-US Fusion-Guided Focal Laser Ablation System at 97th Annual WSAUA Conference
Company Goal to Enable Minimally-Invasive, Focal Therapy Procedure to be Performed in an Office Setting or Clinic under Local Anesthetic
INDIAN WELLS, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- (publ) (CLS), developer of high precision, image-guided focal laser ablation (FLA) systems, today announced the new generation of its is being exhibited at the Western Section AUA - 97th Annual Meeting at Indian Wells, CA this October 31 to Nov 4, 2021. The new TRANBERG thermal therapy system is undergoing clinical studies and being tested using MRI-US, fusion-guided laser ablation for the minimally-invasive, targeted focal therapy of prostate tumors. CLS’s goal is to enable high precision, focal laser ablation of prostate cancer tumors to be performed under local anesthetic in an office setting or clinic as well as hospitals. Visit the company at booth # TT24.
“We’re excited to show our new TRANBERG thermal therapy system to this prestigious group of urologist physician attendees,” stated Michael Magnani, Managing Director of CLS Americas. “CLS is pleased by the growing acceptance in minimally invasive, MRI-US fusion-guided biopsies and cryoablation of prostate cancer tumors. We believe our focal laser ablation system will perform well and produce excellent results using the same fusion-guidance technology.”
High Precision Thermal Therapy System
The TRANBERG® |Thermal Therapy System has been developed for image-guided, high-precision soft tissue thermal therapy and ablation procedures. For the US market, the system is configured for CT or MRI-US, fusion image-guided procedures, and can be configured for tissue temperature feedback for precise temperature and ablation control. It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, external tissue temperature probe sensors, and procedure specific accessories. Its non-cooled, laser fiber technology optimizes heat distribution, eliminates the need for external cooling, and helps reduce procedure times.
About Clinical Laserthermia Systems
Clinical Laserthermia Systems AB (publ) develops and commercializes its including sterile disposables and accessories, for image-guided, minimally invasive focal laser ablation of soft tissue. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: 9. E-mail: . US Tel: 1 (949) 504-5440. For more information about CLS, visit the Company's website: .
This press release was submitted by the contact person below on 2nd November 2021, at 12:00 PM CET Company Contact: Clinical Laserthermia Systems Americas Inc (CLS Americas) Michael Magnani, Managing Director T: E: Media Contact: TopSpin Communications Joe Waldygo, President P: E:
